CHARLES RIVER LABORATORIES INTERNATIONAL INC Form 8-K

June 14, 2018

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 14, 2018

Exact Name of Registrant as Specified

in Charter;

Commission File

Number

State of Incorporation;

Address and Telephone Number

Former Name or Former Address, if Changed since Last

Report

001-15943 Charles River Laboratories International, Inc.

Delaware

251 Ballardvale Street

06-1397316

IRS Employer

Identification

Number

Wilmington, Massachusetts 01887 (781) 222-6000 N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

The consent of PricewaterhouseCoopers LLP dated June 14, 2018, attached as Exhibit 23 hereto, is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
Exhibits.
23 Consent of Independent Registered Public Accounting Firm dated June 14, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 14, 2018 (Registrant)

By:/s/ Matthew Daniel
Name: Matthew Daniel

Title: Corporate Senior Vice President & Deputy General Counsel